Clinical & Translational Oncology最新文献_第5页

SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. SEOM-AEEMT关于职业性癌症和癌症相关残疾的共识。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-16 DOI: 10.1007/s12094-025-04037-2

Laura Mezquita, Mª Teófila Vicente-Herrero, Patricia Cruz, Mª Victoria Ramírez Íñiguez de la Torre, Julia Hidalgo-Coloma, Luisa Capdevila García, Oscar Gallego, Aitana Calvo, Katerine Martínez, Javier Pérez-Altozano, Raquel Molina, Miguel García-Pardo, Laura Gutiérrez-Sainz, Elena Moreno-Atahonero, Martín Oré-Arce, César Serrano, María Jesús Terradillos-García, María Rosario Valero, Luís Reinoso-Barbero, César A Rodríguez, Beatriz Calvo-Cerrada

{"title":"SEOM-AEEMT consensus on occupational cancer and cancer-associated disability.","authors":"Laura Mezquita, Mª Teófila Vicente-Herrero, Patricia Cruz, Mª Victoria Ramírez Íñiguez de la Torre, Julia Hidalgo-Coloma, Luisa Capdevila García, Oscar Gallego, Aitana Calvo, Katerine Martínez, Javier Pérez-Altozano, Raquel Molina, Miguel García-Pardo, Laura Gutiérrez-Sainz, Elena Moreno-Atahonero, Martín Oré-Arce, César Serrano, María Jesús Terradillos-García, María Rosario Valero, Luís Reinoso-Barbero, César A Rodríguez, Beatriz Calvo-Cerrada","doi":"10.1007/s12094-025-04037-2","DOIUrl":"https://doi.org/10.1007/s12094-025-04037-2","url":null,"abstract":"Cancer is one of the main causes of morbidity and mortality in Spain and has a significant impact in the workplace, where exposure to carcinogens in the work environment can increase the risk of developing this disease. The lack of communication between oncologists and occupational physicians limits the accurate assessment of cancer as an occupational disease and as a cause of disability. In 2020, the Spanish Society of Medical Oncology (SEOM) and the Spanish Association of Occupational Medicine Specialists (AEEMT) launched a joint initiative to strengthen prevention, reporting, and management of occupational cancer. This consensus provides a structured framework for assessing the occupational origin of cancer, facilitating case notification and classification as occupational contingencies, and supporting informed evaluations of disability and work reintegration in patients with cancer. The collaboration between both societies aims not only to advance occupational cancer prevention but also to promote evidence-based strategies for return-to-work planning.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis. 新一代测序（NGS）识别晚期非小细胞肺癌可操作突变的诊断准确性：系统评价和荟萃分析

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-13 DOI: 10.1007/s12094-025-04040-7

Nicolás Téllez Castillo, Ana M Goyeneche-García, Luisa M Montoya Quesada, Oscar A Gamboa Garay, Ricardo E Bruges Maya

{"title":"Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.","authors":"Nicolás Téllez Castillo, Ana M Goyeneche-García, Luisa M Montoya Quesada, Oscar A Gamboa Garay, Ricardo E Bruges Maya","doi":"10.1007/s12094-025-04040-7","DOIUrl":"https://doi.org/10.1007/s12094-025-04040-7","url":null,"abstract":"Purpose: To evaluate the diagnostic accuracy and clinical performance of next-generation sequencing (NGS) compared to conventional techniques for detecting actionable mutations using tissue or liquid biopsy samples in patients with advanced non-small cell lung cancer.Methods: A systematic review and meta-analysis of diagnostic test studies (PROSPERO: CRD42023450465) were conducted. We included studies with sufficient comparative data, using a t test to analyze turnaround time differences and hypothesis testing for valid result proportions (p < 0.05). The meta-analysis, performed in Stata 17®, pooled sensitivities and specificities by mutation and evaluation technique. The QUADAS-2 tool assessed study quality.Results: A total of 56 studies involving 7143 patients were analyzed. No significant differences were found in valid result percentages between standard tests and NGS in tissue (85.57% vs. 85.78%; p = 0.99) and liquid biopsy (81.50% vs. 91.72%; p = 0.277). Liquid biopsy had a significantly shorter turnaround time (8.18 vs. 19.75 days; p < 0.001). NGS demonstrated high accuracy in tissue for EGFR (sensitivity: 93%, specificity: 97%) and ALK rearrangements (sensitivity: 99%, specificity: 98%). In liquid biopsy, NGS was effective for EGFR, BRAF V600E, KRAS G12C, and HER2 (sensitivity: 80%, specificity: 99%) but had limited sensitivity for ALK, ROS1, RET, and NTRK rearrangements.Conclusions: NGS enables comprehensive mutation analysis, particularly for point mutations. Further validation is required to improve the detection of gene rearrangements.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review. 胰腺癌少转移性疾病：治疗目的手术是否有作用？叙述性评论

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-12 DOI: 10.1007/s12094-025-04049-y

César P Ramírez-Plaza, Marta Roldón-Golet, José A Pérez-Daga, Fernando Pereira-Pérez

引用次数: 0

Diagnostic and prognostic significance of circulating extracellular vesicles in gastrointestinal cancers. 循环细胞外囊泡在胃肠道肿瘤中的诊断和预后意义。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-12 DOI: 10.1007/s12094-025-04055-0

Ankita Arora, Vinit Sharma, Anikait Kaushal, Anjali Aggarwal

{"title":"Diagnostic and prognostic significance of circulating extracellular vesicles in gastrointestinal cancers.","authors":"Ankita Arora, Vinit Sharma, Anikait Kaushal, Anjali Aggarwal","doi":"10.1007/s12094-025-04055-0","DOIUrl":"https://doi.org/10.1007/s12094-025-04055-0","url":null,"abstract":"Gastrointestinal (GI) cancers represent a significant global health burden, accounting for over one-third of cancer-related deaths globally. Regardless of advancements in treatment procedures, the high mortality rate underscores the crucial need for novel diagnostic biomarkers and therapeutic strategies. Extracellular vesicles (EVs) appeared as fundamental facilitators of intercellular interaction, influencing gene expression as well as cellular function through the transfer of nucleic acids, proteins, and lipids. EVs play dual roles in maintaining intestinal homeostasis under physiological conditions and driving tumorigenesis in pathological states. In GI cancers, EVs contribute to tumor progression by modulating the tumor microenvironment (TME), promoting angiogenesis, epithelial-to-mesenchymal transition (EMT), immune evasion, and metastasis. Moreover, EVs portray a vital role in creating pre-metastatic site, reprogramming immune cells, and facilitating therapeutic resistance through the transfer of resistance-associated molecules. The clinical potential of EVs extends to their utility as liquid biopsy biomarkers, offering a non-invasive approach for early diagnosis, prognostication, and treatment monitoring. EV-miRNAs and EV-long non-coding RNAs demonstrate significant diagnostic and prognostic value in GI cancers. This review provides a widespread impression of the biogenesis, molecular properties, and functional roles of EVs in GI cancers, with a focus on their clinical utility.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives. 一次或两次超分割放疗治疗局限性前列腺癌：证据回顾和未来展望。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-10 DOI: 10.1007/s12094-025-04041-6

Miguel Angel Berenguer-Frances, Abrahams Ocanto, Thomas Zilli, Fernando Lopez-Campos, Francisco Celada, Alfonso Gomez-Iturriaga, Alison Tree, Stefano Arcangeli, Felipe Couñago

{"title":"Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives.","authors":"Miguel Angel Berenguer-Frances, Abrahams Ocanto, Thomas Zilli, Fernando Lopez-Campos, Francisco Celada, Alfonso Gomez-Iturriaga, Alison Tree, Stefano Arcangeli, Felipe Couñago","doi":"10.1007/s12094-025-04041-6","DOIUrl":"https://doi.org/10.1007/s12094-025-04041-6","url":null,"abstract":"This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience. While single-dose outcomes are often suboptimal, two-fraction regimens-especially in HDR brachytherapy-are widely used and may better preserve normal tissues and reduce toxicity. Studies utilizing advanced imaging, real-time motion management, and adaptive planning improve treatment accuracy. Two-session approaches appear safe and effective in the short to intermediate term, though long-term data for single-session SBRT remain limited. The review emphasizes tailoring treatment based on patient factors, tumor characteristics, and institutional capabilities, and calls for further research to refine ultra-hypofractionated radiotherapy protocols for prostate cancer.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review. 接受新型抗体-药物偶联物治疗的妇科癌症患者眼毒性的管理：一篇叙述性综述。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-09 DOI: 10.1007/s12094-025-04050-5

Giuseppa Scandurra, Filippo Marano, Vittorio Gebbia, Maria Rosaria Valerio, Daniela Sambataro, Valentina Lombardo, Giuseppe Angelico, Paolo Scollo, Giuseppe Scibilia, Alessandra Pizzo

{"title":"Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.","authors":"Giuseppa Scandurra, Filippo Marano, Vittorio Gebbia, Maria Rosaria Valerio, Daniela Sambataro, Valentina Lombardo, Giuseppe Angelico, Paolo Scollo, Giuseppe Scibilia, Alessandra Pizzo","doi":"10.1007/s12094-025-04050-5","DOIUrl":"https://doi.org/10.1007/s12094-025-04050-5","url":null,"abstract":"Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life. This review summarizes current evidence on the incidence, pathophysiology, and clinical presentation of ADC-related ocular adverse events in gynecologic oncology. It also provides practical, evidence-based strategies for the prevention, monitoring, and management of these adverse events. Interventions include prophylactic topical therapies, supportive care measures, treatment delays or dose modifications, and herpes zoster vaccination. Comprehensive management of ocular toxicities is essential to ensure the safe and sustained use of ADCs, preserving both therapeutic benefit and patient well-being. Further research is warranted to optimize preventive and management protocols.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. 卵巢癌患者PARP抑制剂相关血栓形成：西班牙肿瘤医学学会（SEOM）血栓形成与癌症组的研究

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-07 DOI: 10.1007/s12094-025-04048-z

Manuel Sánchez Cánovas, Javier López Robles, Francisco José García Verdejo, Diego Cacho Lavin, Helena Olivares, Alberto Garrido Fernández, Eva Coma Salvans, Teresa Quintanar Verduguez, Carmen Salvador Coloma, David Fernández Garay, José David Cumplido, Ana Isabel Ferrer Pérez, Anna Carbó Bagué, Francisco Javier Teigell Muñoz, Ruben García López, Andrea Martínez Marin, Andrés J Muñoz Martín

{"title":"PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.","authors":"Manuel Sánchez Cánovas, Javier López Robles, Francisco José García Verdejo, Diego Cacho Lavin, Helena Olivares, Alberto Garrido Fernández, Eva Coma Salvans, Teresa Quintanar Verduguez, Carmen Salvador Coloma, David Fernández Garay, José David Cumplido, Ana Isabel Ferrer Pérez, Anna Carbó Bagué, Francisco Javier Teigell Muñoz, Ruben García López, Andrea Martínez Marin, Andrés J Muñoz Martín","doi":"10.1007/s12094-025-04048-z","DOIUrl":"https://doi.org/10.1007/s12094-025-04048-z","url":null,"abstract":"Purpose: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).Methods/patients: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan-Meier survival analysis.Results: The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p < 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876.Conclusions: BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology. 利用生物标志物指导食管癌免疫治疗：迈向精准肿瘤学。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-06 DOI: 10.1007/s12094-025-04051-4

Amany I Almars, Sameerah Shaheen, Nahlah M Ghouth, Iman S Abumansour, Asim Abdulaziz Khogeer, Fayez Alsulaimani, Ahmed M Basri, Nasser A Elhawary, Tabinda Hasan, Hailah M Almohaimeed

{"title":"Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.","authors":"Amany I Almars, Sameerah Shaheen, Nahlah M Ghouth, Iman S Abumansour, Asim Abdulaziz Khogeer, Fayez Alsulaimani, Ahmed M Basri, Nasser A Elhawary, Tabinda Hasan, Hailah M Almohaimeed","doi":"10.1007/s12094-025-04051-4","DOIUrl":"https://doi.org/10.1007/s12094-025-04051-4","url":null,"abstract":"Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses. This underscores the urgent need for predictive biomarkers that can identify patients most likely to benefit from immunotherapeutic interventions. Biomarker-based patient stratification can improve treatment outcomes, prevent unnecessary exposures, and conserve healthcare resources. This review explores established and emerging biomarkers for predicting response to immunotherapy in EC. We discuss these biomarkers by categorizing them into four major groups: (i) tumor-related biomarkers (PD-L1 expression, tumor mutational burden, and microsatellite instability), (ii) tumor-immune microenvironment-related biomarkers (tumor-infiltrating lymphocytes and immune cell subtypes and ratios), (iii) blood-based biomarkers (circulating tumor DNA, exosomes, and soluble proteins), and (iv) microbiomes (oral, esophageal, and gut microbiomes). In addition, Advancements in biomarker discovery technologies such as high-throughput sequencing, multi-omics approaches, artificial intelligence and machine learning, single-cell analysis, and liquid biopsy are also discussed for their potential to refine biomarker identification and clinical application.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain. 晚期毒性的管理和青少年和青年癌症幸存者的具体随访需求：来自西班牙科学协会的建议。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-04 DOI: 10.1007/s12094-025-04047-0

Alejandro Pérez Fidalgo, Pilar Alonso, Maitane Andión, Adela Cañete, Erica Collado, Carmen Garrido Colino, José Gómez Codina, Xavier Díaz Carrasco, Ramón García Sanz, Sergio Hernández Expósito, Teresa Lopez-Fernandez, Gabriela Medin, Antonio Molinés, Alberto Moreno Vega, Mónica Ramos, Iñigo San Miguel, Joaquín Sánchez García, Fátima Santolaya

引用次数: 0

Comparison of clinical characteristics and survival between HER2-zero and HER2-low in early breast cancer: a retrospective observational study. 早期乳腺癌中her2 - 0和HER2-low的临床特征和生存率的比较：一项回顾性观察研究

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-03 DOI: 10.1007/s12094-025-04053-2

Violeta Núñez Álvarez, Belén González Castilla, Belén Fernández Rivero, María Hernández Carrasco, Jaime Lluch Gómez, Irene Sánchez Lobón, María Ángeles Ocaña de la Rosa, Yulema Menguiano Romero, Eduardo Perdomo Zaldívar, Lourdes Rodríguez Pérez, Encarnación Benítez Rodríguez, José Manuel Baena Cañada

{"title":"Comparison of clinical characteristics and survival between HER2-zero and HER2-low in early breast cancer: a retrospective observational study.","authors":"Violeta Núñez Álvarez, Belén González Castilla, Belén Fernández Rivero, María Hernández Carrasco, Jaime Lluch Gómez, Irene Sánchez Lobón, María Ángeles Ocaña de la Rosa, Yulema Menguiano Romero, Eduardo Perdomo Zaldívar, Lourdes Rodríguez Pérez, Encarnación Benítez Rodríguez, José Manuel Baena Cañada","doi":"10.1007/s12094-025-04053-2","DOIUrl":"https://doi.org/10.1007/s12094-025-04053-2","url":null,"abstract":"Purpose: Human epidermal growth factor receptor 2 (HER2)-negative breast cancer includes HER2-zero and HER2-low tumors. Whether their clinical features and survival are different is not fully clarified. The objective was to explore their clinicopathologic differences and survival.Methods/patients: Retrospective analysis of HER2-negative, stage I-III breast cancer patients from 2006 to 2016 at a single site. Clinicopathological variables, events and survival are analyzed, comparing HER2-low and HER2-zero cases.Results: Of 535 patients, 351 (65.61%) were HER2-zero and 184 (34.39%) HER2-low (154 (83.70%) score 1 + and 30 (16.30%) score 2 +). The proportion of premenopausal women was higher in the HER2-low subgroup (50.50% vs 39.40%, p = 0.016). For those with HER2-zero tumors, 15.70% were estrogen receptor (ER) negative, whereas only 9.20% (p = 0.045) of HER2-low tumors were ER negative. In HER2-low/ER negative tumors, tumor size, histologic grade, and Ki67 levels were higher. Patients with HER2-zero/ER-negative tumors were younger, had fewer comorbidities, less nodal involvement, a higher frequency of ductal histopathology, and, again, higher histologic grade and Ki67 levels. There were no differences in the events. The overall survival probability at 11.50 years in the HER2-zero subgroup was 0.51 (95% confidence interval (CI 95%) 0.28-0.74) and in the HER2-low subgroup 0.67 (95% CI 0.56-0.77) (p = 0.52).Conclusions: HER2-zero and HER2-low breast cancers are not distinct clinicopathologic entities. The differences detected in some variables seem to depend on ER status. No prognostic differences were observed.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0